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The Vascular Research Laboratory Experience 
In the summer of2001, I worked in a Vascular Research Laboratory (VRL). This senior 
project attempts to give a holistic approach to the experience by revealing three areas: 1) An 
overview ofthe VRL at The University of Tennessee Hospital in Knoxville 2) A summary of 
basic laboratory techniques learned 3) A paper on the research and experiments I performed this 
summer. 
The VRL works in direct contact with the Division of Vascular Surgery to study new 
techniques and solutions to problems encountered during surgery. The laboratory also exists as 
part of the curriculum for fellows, residents, and graduate students, as well as an educational 
laboratory for undergraduate students interested in research and/or medicine. 
Mastering basic laboratory techniques creates the foundation of any researcher. The 
VRL emphasizes cell and tissue culture, cell morphology, gel electrophoresis, protein assay, 
immunohistochemistry, protein isolation, aseptic technique, densitometry, and buffer 
formulation. An attempt is made in the paper to acquaint a researching neophyte with these 
techniques to ease the transition and shorten the time introducing these procedures when needed. 
The actual research and experiments accomplished this summer comprises the last 
segment. An emphasis is placed on isolating smooth muscle cells from other cell types in the 
artery, especially from the fibroblasts, using fluorescent techniques. This project hypothesizes 
that fluorescent labeling might provide a faster and less expensive way to collect pure human 
aortic smooth muscle cells at low passages. An overview of a heat shock protein (HSP-70) 
project studying HSP-70 expression in canine arterial endothelial cells at different localized fluid 
shear stress conditions is also included. 
The Purpose of the Vascular Research Laboratory 
at the 
University of Tennessee Graduate School of Medicine 
The Vascular Research Laboratory at the University of Tennessee Graduate School of 
Medicine is supported through the Surgery Department at the University of Tennessee Hospital. 
The premise is to work in collaboration with the vascular surgeons at the hospital on ideas and 
problems associated with vascular surgery. The laboratory's efforts are based around "rigorous, 
basic and translational research in the biology of the vascular system" (Mission Statement). The 
laboratory focuses on the necessary understanding of cellular interactions and mechanisms in the 
peripheral vessels to better treat vascular disease medically andlor surgically. The Vascular 
Research Lab is dedicated to training talented surgeons in "experimental design, basic and 
advanced cellular techniques, pre-clinical biomedical device evaluation and scholarly 
presentation of experimental data" (Mission Statement). Inclusion of outside investigators, 
graduate students and undergraduate students is considered a strength of the program as it 
introduces non-surgical perspectives which encourage creative solutions and challenge 
assumptions to solve complicated problems. 
The main functions of the lab are as follows: 1) research and training of select surgical 
residents and vascular fellows, 2) ;;upport of clinical research and development projects, 3) basic 
support research and clinical projects requiring technical expertise in tissue and cell 
cryopreservation, cell isolation and cell culture, retroviral insertion of genes into endothelial 
cells, fluorescence activated cell sorting (F ACS) and analysis, protein isolation and Western 
blotting, RNA isolation and Northern blotting, PCR, immunohistochemistry, histologic 
interpretation and lab animal pathology. 
Learned Techniques 
As a Student Assistant in the Vascular Research Lab at UT Hospital in Knoxville, 
Tennessee, I learned many basic techniques that create the foundation of any researcher. An 
emphasis was placed on cell and tissue culture, cell morphology, gel electrophoresis, protein 
assay, immunohistochemistry, protein isolation, aseptic technique, densitometry, and buffer 
formulation. Several of these topics were covered in this section in order to acquaint a 
researching neophyte with these techniques. The desire was to ease the transition and shorten the 
time introducing these procedures when needed. 
CELL CULTURE 
Introduction: 
Cell culture using sterile technique is the process of freezing, unfreezing, growing, and splitting 
specific cells in media compatible for the cells. Sterile work with the cells always occurs in a 
laminar flow hood where the airflow, temperature, and equipment are contained. Cell containers 
should not be opened outside of the hood. A glass window is also used to insure that sterility is 
not comprimised. 
Freezing Cells Back: 
When freezing cells back, media is aspirated off the cells and buffer is added and aspirated to 
wash the remaining media from the cells and the container. Trypsin is added to strip the attached 
cells from the flask or well, taking about 5 minutes. Gentle tapping or incubating may quicken 
the releasing of the cells from the flasks. Once the cells have lifted off of the flask, media with 
serum is added to stop the enzyme trypsin. The cell solution is transferred to a tube and 
centrifuged in a balanced centrifuge for 5 minutes at 1500 rpm. The supernatant is aspirated 
from the tube and the pellet is re-suspended in 0.9mls fetal bovine serum (FBS) and O.lml of 
dripped DMSO and the solution is put in a cryovial. The cryovial is placed in a step-down cryo-
preservation container which is then placed in a -80 degree Celsius freezer. The following day, 
the cryovial is removed from the freezer and placed in liquid nitrogen. The location of the 
cryovial in the liquid nitrogen must be logged. The hood should be sprayed with 70% ethanol. 
Unfreezing Cells: 
When lmfreezing cells, the specified cryovial is taken out the nitrogen tank, and put in a warm 
water bath. The cryovial must remain standing, and water must not cover the top of the vial 
because the cap is porous with the potential to compromise sterility if contacted by water. Once 
tmfrozen, the vial should be sprayed with 70% ethanol excluding the cap. The cells are then 
diluted in the desired amount of media and put into the appropriate flask(s). The media must be 
changed the following day. The hood should be sprayed with 70% ethanol. 
Growing Cells: 
Growing cells are contained in flasks or wells, depending on the desired amotmt and usage .. 
They are kept in incubators that maintain a temperature of37 degrees Celsius and a pressure of 
5.0 atm Nitrogen, which optimizes growth. Cells must be kept in media that is best for the type 
of cell growing. Typical media includes IMDM (Iscores Modified Dulbecco's Media, Sigma 
Inc, St. Louis, MO), SMGM2 (Smooth Muscle Growth Media, Clonetics), DMEM (Dulbecco's 
Modified Eagle's Media), and EGM (Endothelial Growth Media), and all include 10 % FBS. 
Splitting Cells: 
When splitting cells, the cells are typically confluent from growth in a flask. Media is aspirated 
off the cells, and CMF is added and aspirated to wash the remaining media from the cells and the 
container. Trypsin, using half of the amount of media used to grow the cells, is added to strip the 
attached cells from the flask or well, taking about 5 minutes. Gentle tapping or incubating may 
quicken the stripping. Once the cells have lifted off of the flask, media with serum is added in 
the same amount as the trypsin. The cell solution is transferred to a tube and centrifuged in a 
balanced centrifuge for 5 minutes at 1500 rpm, (Notice, this is the same procedure as that for 
freezing cells back thus far). The supernatant is aspirated from the tube and the pellet is re-
suspended in a volume or media divisible by the split. For instance, if splitting the cells into 3 
different flasks, the pellet may be re-suspended in 3 mls of media. The media should be spread 
all over the side growing the cells to insure equal growth throughout the flask. The flasks should 
be labeled appropriately with a change of passage number and placed in the incubator. The hood 
should be sprayed with 70% ethanol. 
IMMUNOHISTOCHEMISTRY 
Introduction: 
Immunohistochemistry is not considered a sterile technique. 
Technique: 
The tissue is embedded in paraffin. The embedded tissue is secured in a Jung histocut. The 
tissue is angled in the holder so that the embedded block is perpendicular and parallel to the 
razor to minimize wasteful cutting and to insure the entire tissue is cut in each slice. Sharp razors 
should be used at all times during the cut to ensure clean cuts, so safety is extremely important. 
A safeguard should be placed on the razor at all times the histocut is not being used, or the razor 
should be removed. Anytime the embedded tissue is not being cut, especially when positioning 
the tissue, the wheel should be in a locked position. Most tissue cuts have a thickness between 4 
and 6 micrometers. The tissue is cut in bands with a manually-controlled wheeL If the tissue is 
not cutting well, the tissue and paraffin can be frozen with an aerosol freezer and/or hydrated 
with water. Once several cuts have been made insuring that the entire section is included, the 
bands are transferred to a water bath of 40 degrees Celsius. Fixation solution can be put in the 
water to aid in mounting on the slides. Each slide is angled in the water bath to pick up a slice of 
the embedded tissue. The slide is allowed to dry. The slide is placed on a hot plate to melt the 
paraffin. The slide(s) are placed in slide books to await the desired staining. Typical stains 
include H and E (Hematoxylin and Eosin) to stain the cytoplasm and nucleus, Smooth Muscle 
Alpha Actin to stain smooth muscle cells, antibody additions for adhesion, and quadrochrome to 
stain smooth muscle cells, collage.n, endothelial cells and elastin, (mostly for vessels). 
PROTEIN MEASUREMENTS 
Introduction: 
Most protein measurements do not have to be sterile. The protein measurements include protein 
isolation or extraction, protein assay, and Western blotting using gel electrophoresis. 
Protein Isolation: 
Using a nuclear and cytoplasmic extraction kit, non-denatured proteins can be purified in less 
than two hours. Protease inhibitors as well as Cytoplasmic and Nuclear extraction Reagents 
(CER and NER) (Pierce Co., Rockford, 11) are made in the specified concentrations. CER I is a 
hypotonic solution so that cells swell. CER II is a detergent that makes holes in the cells so that 
the intracellular components excluding the nucleus exit the cell membrarie. NER is added 
causing the cell to shrink and nucleus to exit the cell membrane. NER is only needed if nuclear 
proteins are desired. 
Homogenizing tissue: 
1 ml of PBS is added to each specimen. 2 tubes are filled with 50 ml of isopropyl alcohol and 2 
tubes are filled with de-ionized water. The homogenizing blade is washed in a tube of de-
ionized water. The tissue is then homogenized, which is simply grounding the tissue so that it is 
well mixed. The blade is then washed with water, alcohol, and then PBS. The steps can be 
repeated as needed for each speci(Ilen. Once all of the specimens are homogenized, they are 
centrifuged at 1,000 G's for 5 minutes. 1.5 ml microfuge tubes are labeled appropriately. 100 ul 
of CER I plus some extra is obtained for each vial. Protein inhibitors are added to the CER I in 
the correct concentration, as noted in the extraction kit. The new CER I solution is kept on ice. 
Before adding the CER I to the specimens, the supernatant is taken off of the centrifuged tubes. 
The pellet is resuspended in 0.5 ml of PBS and transferred to smaller vials. The new vials are 
centrifuged at 500 G's for 2 minutes. The supernatant is aspirated, and 100 ul ofthe chilled CER 
I is added to each pellet. The pellet is re-suspended via vortex at the highest setting for 15 
seconds. The new solution is incubated on ice for 10 minutes. After incubation, 5.5 ul CER II is 
added to each vial. The solution is vortexed again for 5 seconds on the highest setting. It is then 
centrifuged for five minutes at the highest setting. The tubes are then put on ice. The 
supernatant, which is the cytosolic protein, is extracted and stored quickly. Care is taken not to 
get too close to the pellet. 
Protein Assay: 
Using a protein assay kit and the Lowry procedure, protein specimens can be measured against a 
standard. The goal is to generate a graph of absorbance versus concentration against the 
standards. Protein standard solutions are made using the given directions in the protein assay kit 
and vials are labeled appropriately. The concentrations are typically the following: 
Standard # Protein concentration Protein Standard Solution Water (ul) 
(uglul) (ul) 
1 0 0 1000 
2 5 125 987.5 
3 10 25 975 
4 25 62.5 937.5 
5 50 125 875 
6 100 250 750 
7 200 500 500 
Mixtures are made with 10 uls of each sample and 990 uls of water. Starting with the least 
amount of water concentration needed, the water is added for the standards and then the correct 
amount of water is added to the samples. Next, 1 ml of Lowry's Reagant is added to every tube 
including the standards and the samples. Each tube is vortexed at minimum speed and then sit 
for 20 minutes. While vortexing for quick and immediate mixing, 0.5 ml of folin is added. The 
solutions sit for 30 minutes and the spectrophotometer is turned on. All the solutions are then 
taken to the spectrophotometer. On the spectrophotometer, the quantitative route is chosen, and 
parameters are changed to print the seven standards, and concentrations are entered. Then, 1 ml 
of water is added to each cuvet, and auto-zero is pressed. The cuvets should be placed such that 
the clear sides face sideways and the rippled sides face the front and back. Care should be taken 
not to touch the cuvet on the flat, clear sides so that the results are not skewed. The front cuvet is 
discarded and 1 ml of each solution is added, going through the standards first, using a new cuvet 
each time. The results are printed with a graph of the standard to insure there is a small deviation 
from the expected results, and a table reporting the unknown concentrations of the protein 
samples. The desired mass is typically around 30 ug. In order to obtain the desired amount of 
mass from each sample, the desired mass should be divided by the concentration, and the 
quotient is the volume needed for ~ach sample to have that mass. Sometimes, samples must be 
re-concentrated because the amount is too small or large for the desired masses. 
Microconcentrators with filters are used. Frozen vials are thawed and 90 uls of each sample is 
used and centrifuged. 
Project: Isolating Aortic Smooth Muscle Cells via Fluorescent Markers 
Background: 
Current techniques to sort aortic smooth muscle cells from arterial tissue are both 
expensive and inefficient. The current method available physically sorts the smooth muscle 
cells, and the only one available for the University of Tennessee at Knoxville is at the Veterinary 
School. 
This experiment attempts to test a possible alternative to current methods of obtaining 
pure lines of smooth muscle cells by chemically labeling smooth muscle cells and fibroblasts. 
Using Levamisole and Vector Red (Vector Lab Inc, Burlingame, CA), an attempt will be made 
to use these fluorescent markers as flags to sort the smooth muscle cells from the artery. If 
successful, this method would be useful in identifying and then obtaining the smooth muscle 
cells separated from the rest of the artery. Not only would it be cheaper, but sorting could be 
accomplished easily in any lab. 
Experiment: 
Canine Fibroblasts (K9 Fibre) and Human Aortic Smooth Muscle Cells (HuAOSMC) 
were pulled from the storage freezer and grown separately in T-25 and T-75 flasks in Dulbecco's 
Modified Eagle's Media (DMEM~ and Iscores Modified Dulbeccos's Media (IMDM), 
respectively. Once confluent, (and the fibroblasts were confluent much sooner), the cell lines 
were each plated in wells at varying concentrations (see table below). These solutions were then 
each tested with Vector Red and Levamisole. to determine the best concentration for viability and 
fluorescence of the cells with the markers. 
Vector Red was made using one drop of the A, B, and C alkaline phosphotase droppers 
for every 2.5 mL of 100mM Tris-HCL. 1 mL of this new solution was mixed with every 9 mLs 
of PBS. The final solution was then filter sterilized using a syringe and a .02 micron filter with 
acrodiscs. The Vector Red should be added first in the dark, and incubated immediately because 
Vector Red reacts with light and is less sensitive the longer the final solution sits. 
The Levamisole solution was made using 2 drops of Levamisole per 2.5 mLs of 100 mM 
Tris-HCL. 
When checking for toxicity and flow, the amounts used with the fibroblasts were as follows: 
Cells Treated with Vector Red 
Well Concentration Amount Vector Red Amount Media 
1 100 2ml Oml 
2 1:10 200 ul 1.8 ml 
3 1:100 20 ul 1.98 ml 
4 1:500 4ul 1.996 ml 
5 1:1000 2 ul 1.998 ml 
6 Control (0) Oml 2ml 
Cells Treated with Levamisole 
Well Concentration Amount Levamisole Amount Media 
1 1:25 80 ul 2ml 
2 1:50 40 ul 2ml 
3 1:100 20ul 2ml 
4 1:200 10 ul 2ml 
5 1:400 5 ul 2ml 
6 2:25 160 ul 2ml 
Note: The control used in the wells treated with Vector Red also served as the control for the 
wells treated with Levamisole. 
After 16 hours of incubation with the mixed solutions, the wells were observed under 
microscopes to get approximations of dead cells which look rounded and/or floating versus 
viable which are flat and attached to the plate. The following observations were made: 
Cells Treated with Vector Red 
Well Concentration of solution Approximate Percent dead 
(floating) 
1 100% 90% 
2 1 :10 10% 
3 1:100 <5% 
4 1:500 <1% 
5 1:1000 <1% 
6 Control (0 %) <1% 
It should also be noted that Wells 5 and 6 appeared to have more dead cells because of 
over-confluency. 
Well Concentration of solution Approximate Percent dead 
(floating) 
1 1:25 10% 
2 1:50 5% 
3 1:100 <5% 
4 1:200 <5% 
5 1:400 <1% 
6 2:25 90% 
It should be noted that wells 1-5 follow a decreasing concentration pattern, while well 6 
had the highest concentration of Levamisole. 
The cells from each well were then counted with a Hemocytometer using protocol VRL-
SOP-607 (Vascular Research Lab-Standard Operating Procedure-607). Each of the 6 wells were 
trypsinized, i.e. sloughed from the plate to allow mobility of cells. They were then centrifuged 
for five minutes at 1500 rpm's. They were each re-suspended in 1 ml of media (DMEM). Using 
Trypan Blue the cells were counted. 
The remaining cells treated with Vector Red were then tested in flow conditions with a 
histogram by means of a F ACS machine, (Fluorescent Activated Cell Sorting machine). First, 
they were re-centrifuged for five minutes at 1500 rpm's. The supernatant was aspirated and the 
pellet was re-suspended in 1 ml 1 % PBS. The solutions were put through the F ACS machine. 
Human Aortic Smooth Muscle Cells were also grown in two 6-well plates in SMGM2 
(Smooth Muscle Growth Media 2) and when confluent, where treated with Vector Red and 
Levamisole in the following concentrations: 
Cells Treated with Vector Red 
Well Concentration Amount Vector Amount Media 
Red (SMGM2) 
1 1:10 200 ul 1.8 ml 
2 1:40 50 ul 1.95 ml 
3 1:200 10 ul 1.99 ml 
4 1:400 5 ul 1.995 ml 
5 1:1000 2 ul 1.998 ml 
I Control (0) 
Cells Treated with Levamisole 
Well Concentration Amount Amount Media 
Levamisole (SMGM2) 
1 1:40 50 ul 1.95 ml 
2 1:200 10 ul 1.99 ml 
3 1:400 5 ul 1.995 ml 
4 1:1000 2 ul 1.998 ml 
5 1:1:100 10 ul Vector Red 1.98 ml 
10 ul Levamisole 
6 Control (0) Oml 2ml 
It should be noted that wells 5 and 6 were accidentally mixed. 
After sixteen hours, the dead cells and viable cells were counted using Trypan Blue and a 
Hemocytometer using Standard Operating Procedure VRL-SOP-607 . Each well was trypsinized 
by aspirating the media, washing in CMF, aspirating the CMF, releasing with 1 mloftrypsin, 
and diluting in 1 ml SMGM2. 25 uls were taken of each sample in a 1.5 ml tube and 500 ul 
Trypan Blue and 475 ul CMF were added to the 25 uls of cell media. A cover slip was placed on 
top of a clean, dry hemocytometer. Approximately 10 ul of the suspension was added to each 
side of the hemocytometer. The cells were then counted using a given formula. Only cells 
inside the lines counted, and blue ones reflect non-viability. The following results were found: 
Cells Treated with Vector Red 
Well Concentration Viable Non-viable 
1 1:10 0 30,000 
2 1:40 20,000 0 
3 1:200 10,000 0 
4 1:400 10,000 0 
5 1:1000 30,000 10,000 
6 Control (0) 20,000 20,000 
Cells Treated with Levamisole 
Well Concentration Viable Non-viable 
1 1:40 10,000 10,000 
2 1:200 20,000 30,000 
3 1:400 10,000 0 
4 1:1000 10,000 20,000 
5 1:1 :100 0 30,000 
1 Control (0) 1 10,000 
Note: These Smooth Muscle Cells did not grow very well. However, the cells were counted in 
10,000 increments. When taken to FACS, the machine did count almost 5000 cells for each of 
the wells. 
All ofthe remaining solution of cells, trypsin, and SMGM2 was re-centrifuged at 1500 
rpm's for 5 minutes. The supernatant was aspirated, and the pellet was re-suspended in 1 mlof 
1 % PBS. The cell-suspended solution was taken to F ACS. 
The results using the F ACS machine from the canine fibroblasts and the human aortic 
smooth muscle cells were compared. First it was noted that Levamisole and Vector Red 
fluoresced specific cells similarly. This showed that one fluorescent marker did not prove more 
favorable to either fibroblasts or smooth muscle cells. It was decided that Vector Red would be 
the fluorescent marker studied from this point. 
The three fluorescent band pass filters, i.e. FLl, FL2, and FL3, fluoresced best at 530 nM 
for FITCIFLI, 585 nM for PIIPE or FL2, and greater than 650 for RedIFL3. It was also noted 
that the Vector Laboratories repoI1ed that Vector Red excitation is "broad and seems to be from 
360 nm to 560 nm," while the emission spectrum seems to be above 560 nm. 
For every concentration level, the canine fibroblasts fluoresced with one sharp peak just 
less than 101 and ending around 102• The human aortic smooth muscle cells, on the other hand, 
fluoresced with two peaks around 102 and 103• The most intriguing finding was that at a Vector 
Red concentration of 1: 1 0 the smooth muscle cells fluoresced at curves beginning above 102 for 
the FL2 and FL3 with peaks halfway between 102 and 103 as well as 103 and 104• These results 
are not only higher than the fibroblast emissions, but do not even overlap. Thus, the possibility 
of gating the cells at 102 or slightly above could result in a pure smooth muscle cell line. 
Due to availability and unavailability of specific cell lines, cells were grown in 8 wells. 
The first two contained rabbit fibroblasts, the second two contained canine fibroblasts, the third 
two contained human smooth muscle cells T/G ATCC, and the fourth two contained human 
fibroblasts which was confirmed after a negative alpha actin staining test for smooth muscle 
cells. The rabbit fibroblasts and canine fibroblasts were grown in DMEM, the human smooth 
muscle cells were grown in SMGM2, and the human fibroblasts were grown in IMDM. One of 
each of the types of wells was considered a control, to which only media was added, and the 
other had 200 ul of Vector Red to 1.8 ml of media, a concentration of 1:10. The cells were 
incubated for sixteen hours. Upon retrieval they were centrifuged, the supernatant was aspirated, 
and the pellet was re-suspended in Iml 1 % PBS. The canine fibroblasts, wells 3 and 4, did not 
grow very well. It was assumed that they were grown for several days in media without 10% 
FBS, thus killing the cells. 
The results showed the rabbit, canine, and human fibroblasts peaking between 101 and 
102 and tapering quickly above 102. The fibroblast peak completely ends by 103• The human 
smooth muscle cells, on the other .hand, peaked above 103, with an ascending slope sharpening 
halfway between 102 and 103, and remaining high until 104. A mild peak with the smooth 
muscle cells did occur around 102, however, the bulk of the cells remained in the peak to the 
right. 
The goal is to efficiently and inexpensively isolate smooth muscle cells from arterioles so 
that the cost of future research using smooth muscle cells will be reduced, and the availability of 
smooth muscle cells will be increased. 
Heat Shock Protein Project 
Atherosclerosis is a progressive vascular disease causing plaque formation and an 
ensuing occlusion of the vessel lumen. The disease begins with endotheliallesions. It has been 
documented that endothelial lesions result from several local hemodynamic factors such as wall 
shear stress and turbulent flow. It has been reported that adhesivt:: properties of endothelial cells 
are heightened by chronic shear stress. In response to high shear stresses in both in-vivo and in-
vitro models, endothelial cells increasingly express heat shock proteins (HSPs). In direct 
correlation, studies have shown the enhanced adhesive properties would benefit from vascular 
graft implantation. Potentially, HSPs are targets of anti-HSP antibodies at primary endothelial 
lesion sites for decreasing auto-immunogenic activity. A transplant may be at risk of "arterio-
venosclerosis" or post-implantation sclerosis if exposed to arterial hemodynamic conditions, 
which is relevant to the use of vein grafts. 
The goal of this project was to study HSP-70 expression in canine arterial endothelial 
cells at different localized fluid sh.ear stress conditions. Endothelial lesions at the beginning of 
atherosclerosis would be better understood ifHSP-70 expression was upregulated with those 
stress conditions. Using native blood and artery of a canine, the expression ofHSPs could be 
tested in an ex vivo model. An in vitro study occurred using media with the same viscosity as 
blood. This study included a flow apparatus allowing two vascular conduits to be exposed 
simultaneously at two different flow conditions. Further stUdies assessing the expression of other 
molecules including adhesion molecules, could be done using this as a model. The ability to use 
native blood in the flow system makes the model as close to an in vivo model as possible while 
keeping other hemodynamic factors independent. 
In the ex-vivo model, cells from the carotid arteries of dogs were exposed simultaneously 
to different flow conditions via a flow system. Each vessel was exposed to each condition and 
compared. The conditions included normal physiological stress at 15-30 dynes/cm2 and extra-
physiological stress anywhere above 60 dynes/cm2. Blood was the fluid used at a time constant 
of four hours. Distributive analysis was done for intima, media, and adventia layers of the vessel 
using immunohistochemical staining. The staining compared the amount ofHSP-70 expression 
in each layer. Difficulty was encountered cutting the grafts as tissue for slide preparation because 
the grafts were plastic. Protein analysis was also done to quantify the amount of protein in the 
endothelial cells. Two static controls were used. The first static control remained at room 
temperature for four hours before they were frozen. The second static control was tissue placed 
in a petri dish with whole blood in an incubator at 37 degrees Celsius with 5 percent carbon 
dioxide. The staining of the tissues is in progress and is part of on-going research in the 
Vascular Research Lab. 
The Flow System: 
A 2000 ml Erlenmeyer flask was filled with media and a stop cork was used with holes 
for the gas-permeable tubing. A pulse dampener and pulsitile pump were used to pump blood 
into the system. Ti-Cron suture was used to tie the vessels to the connectors. 25 ml pipets were 
used to keep the vessels straight and stable because curvature would skew the results. The flask 
was incubated in water at 37 degrees Celsius to be comparable to human body temperature. A 
trial run was done using water. 
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601 Standard Operating Procedures 
Protocol for splitting cells 
Scope: 
Of 
1 of 3 
.. This SOP will be followed by personnel engaged in research and clinical studies in 
the Vascular Research Laboratory of the Department of Surgery. 
Reagents Required 
a. Clonetics trypsinlEDTA (stored frozen in sliver freezer) 
b. CMF (in hood) _ 
c. Media with serum (in white refrigerator) 
d. 70% Ethanol (next to hood) 
Equipment Required 
a. 10 ml pipette' 
b. Centrifuge tube 
c. Appropriate number ofT-75 flasks 
d. Aspirator-
e. Pipettes 
3. Operation Guidelines 
a. Turn the hood on at least 10 minutes prior to beginning. 
b. Place the Clonetics trypsinfEDTA, CMF, and media with serum in the 
hood and spray with 70% Ethanol. 
, 
c. Place the cells in the hood. 
d. Aspirate the media off the cells. 
e. Place 5 ml of CMF on the cells and slide around flask to cover cells 
completely. 
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g. Place 5 ml of trypsinlEDT A on the cells. 
h. Allow the cells to corne off the surface of the flask for about 5 minutes. 
Watch cells under microscope, tapping gently helps get all of the cells off 
the surface. 
1. Once the cells are off the bottom of the flask, add 5 ml of the media with 
serum to the flask. 
J. Use a 10 ml pipette to pull all of the solution out of the flask to transfer to 
a 15 rnl centrifuge tube. DURING SUCTION INTO 10 i\1L PIPETTE, 
THE CELLS ARE NOT TO EXCEED THE COTTON PROTECTION 
ON THE TOP OF THE PIPETTE. IF THIS OCCURS, THE STERILITY 
OF THE CELLS HAS BEEN CO"tv1PROMISED. 
k. Spin the cells in the centrifuge at 1500 rpm for 5 minutes. MAKE SURE" 
CENTRIFUGE IS BALANCED. ('J.lhcr,) '1"'V,,~. 
(faDlf n~~ -r-1S t\c.~I::.~ ~+~p!'.~,~ (~j\J Med,c~ I Vf7ur i"it,'':''!<;j oIo..+ejwh..,.r ;le,,) 
1. Once the cells have spun, place the tube back in the hood and aspirate off 
the supernatant. BE CAREFUL NOT TO ASPIRATE THE PELLET IN 
THE BOTTOM OF THE TUBE. 
m. Bring the cells up in a volume suitable for the size of your split with 
media. (i.e. 3 mls for a 1:3 split, etc.) 
n. Place the correct amount of cells in a T -75 flask. 
o. Add tbe remaining volume of media to have 10 mls of media in the flask . 
(
e':' d '> 
Spre""-d Meet Ie ovl!..- ) :clc' 
p. Label the flasks and change the passage number. Loosely replace lids and 
place flasks in the incubator. 
q. Clean up hood/working area with 70% ethanol. 
Trouble shooting 
If at any point during the procedure, the sterility of the cells are 
compromised, the cells are to be c!i~posed off or lab_el~~~s being 
-
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b. contaminated until further instructions for course of action from the lab 
supervIsor. 
c. To avoid such problems, the user should sterilize the hood/working area 
with 70% ethanol before starting the procedure. 
d. Be careful not to aspirate the pellet in the bottom of the tubes. 
s. Calibration Instructions 
.NA 
6. Routine Maintenance Instructions and Schedule 
NA 
7. Non-routine maintenance instructions 
NA. 
8. Responsible person(s) 
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Title: Freezing Cells Back 
University of Tennessee 
Medical Center 
Vascular Research Lab 
Standard Operating Procedures 
Iti. -.~ .. 
~~: 
·~ii..; 
Scope' ';~./;"'" . ·,'f· 
This SOP will be followed by personnel engaged in research and clinical studies in 
1. 
the Vascular Research Laboratory of the Department of Surgery. '. 
II. Purpose: 
To describe the procedures for proper freezing of cells back. 
III. Procedures: 
1. Reagents Required'c, ,;.! 
a. TrypsinlEDTA (frozen in silver freezer) 
b. CMF (in hood) 
~ Media with serum (in white refrigerator) 
( c. / d. 'Aliquot of FBS (frozen in silver freezer or "" ..... '-.I.L.>o;~~~~~~ 
Po~ ... ,.,,) e. DMSO (in hood in a foiled 15ml tube) 
f. Thawed Mr .. Frosty (frozen in -80°C freezer at the end of hall) 
g. 70% Ethanol (next to hood) 
2. Equipment Required 
3. 
a. 15ml centrifuge tube 
b. 1mI.-c)'ftw+i:i1 ul'f"'';'''\ 
c. Icc syringe 
d. Aspirator 
e. 10ml pipette 
Operation Guidelines 
a. Turn on the hood at least 10 minutes to beginning. 
b. Spray the hooel/working area with 70% Ethanol. 
,/ ('''';'''1 Q,I~") k ~,,,,,J 
c. Place FBS in water bath until thawed, then place in hood. 
d. PI ace trypsi n/EDT A, eMF and media with serum in hOQd U1H • ....,.. 
~l. 
e. Place cells in hood and aspirate the media off the cells. 
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Standard Operating Procedures 
f. Place 5 ml of eMF on the cells and slide around flask to cover cells 
completely. 
g. Aspirate the CN1F off the cells. 
h. Place 5 ml of trypsinJEDT A on the cells. 
(1) "",~) per ," .. \<.,,\:Cd·c, 
GJ"""i [1po:~ '.ft C~ei'; He: /.." etl11 
fA. t p .... V;)Ive.i J 
,}~dd, :J...'\~' l",,-i·(.y, ,,; tr-)p&i/\ 
1. Allow the cells to come off the surface of the flask for about 5 minutes. 
Watch cells under microscope, tapping gently helps get all of the cells off 
the surface. L \ ~_ ." \'. _-o,,,, 1 .~' : ~ ".'r, . .e.o>-cl ~ _ Ge.l\ tJfe tieL..:.) /(1J'\.h: .. , t'j(X' ,t" "";,,,,,',,, 1..l'.. l -'-') j' )" b"_(C'~j 
) \"be,1 i'\;~i",l) 
J. Once the cells are off the bottom of the flask, add 5 ml of the media with 
serum to the flask. : '''"'1 d.'. \0) 
...,t.. 
K. Use a 10 ml pipette to pull all of the solution out of the flask to transfer to 
a 15 ml centrifuge tube. DURlNG SUCTION lNTO 10 .ML PIPETTE, 
THE CELLS ARE NOT TO EXCEED THE COTTON PROTECTION 
ON THE TOP OF THE PIPETTE. IF TillS OCCURS, THE STERILITY 
OF THE CELLS HAS BEEN CONIPROMISED. 
1. Spin the cells in the centrifuge at 1500 rpm for 5 minutes. MAKE SURE 
CENTRIFUGE IS BALANCED. 
m. Once t~e cells have spun, place the tube back in the hood and aspirate off 
the supernatant. BE CAREFUL NOT TO ASPIRATE THE PELLET IN 
THE BOTTOM OF THE TUBE. W\,.ii cJ", 
~ 'J,\~'l . 
_: ;'00-,,)"''- ~ \"'C 
n. Resuspend the pellet in 0.9 mls of FBS and place in the c~yovial. (oy ;~\, 
cJ!;c: .. ': IT' ;'1'': 1'; pd- , ' 
o. Obt111l1 11 kC synllge and place 0.10 cc of DMSO into the vial, dripping it 
slowly over the cells. UCO~L.) 
p. Label the cryovial appropriately, place it into the Mr. Frosty, and put in 
the -800 C freezer at the end of the hall. 
q. The next day, remove the Mr. Frosty from the freezer and place the 
cryovial in liquid nitrogen. Fill out the liquid nitrogen log book so the 
location of the cells are appropriately documented 
.. -I 
i 
,," n "-. ..;-,..' ,-' . ..,,,.. ,' .... ~.~, .... . 
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a. If at any point during the procedure, the sterility of the cells are 
compromised, the cells are to be disposed off or labeled as being 
contaminated until further instructions for course of action from the lab 
supervisor. 
b. To avoid such problems, the user should sterilize the hood/working area 
with 70% ethanol before starting the procedure. 
c. Be careful not to aspirate thepellet in the bottom of the tubes. 
Calibration Instructions 
NA 
Routine Maintenance Instructions and Schedule 
Alcohol in the Mr. Frosty should be changed after 5 uses. Allow the Mr. 
Frosty to thaw after rempving from the freezer. 
Non-routine maintenance instructions 
NA 
Responsible person(s) 
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JE-PERTM Nuclear and 
:...-,toplasmic Extraction Reagents 
~ 333 
" duct Description 
Description 
NE-PERTM Nuclear and Cytoplasmic Extraction Reagents 
3747 N. Meridian Road 
P.O. Box 117 
Rockford, IL 61105 
0872w 
This kit supplies a complete set of lysis reagents that enable the separation of nuclear extract and 
cytopla,smic fractions from cultured cells and tissue. The optimized reagents and protocol allow 
non-denatured, active proteins to be l1urified in less thanlWo hours. This kit contains sufficient 
cytoplasmic and nuclear extraction reagents for extracting 50 cell pellet fractions with a packed 
cell volume of 20 f1I (a total of -2.0 g of cell paste). 
Kit Contents 
Instructions for Use 
i\> :erials 
Cytoplasmic Extraction Reagent I (CER I), 10 ml 
Cytoplasmic Extraction Reagent II (CER 1I), 550 III 
Nuclear Extraction Reagent (NER), 5 ml 
A Mammalian cells from whole tissue or cultured cells 
&.-- Protease inhibitors: 
Nuclear and cytoplasmic extraction can be done without the use of protease inhibitors. For optimal results, 
however, we recommend using a mixture of the following protease inhibitors at the indicated final concentrations. 
-'" 
Inhibitor rStockl 
Benzamidine 250 m2Jml 
Aprotinin 2 mg/ml 
Leupeptin 2 mg/ml 




0.5 mg/ml N/A 
2 ug/ml N/A 












'",/0 0 0 
1'.IDOO 
-. ,following protocol reflects reagent volumes based on samples with a packed cell volume of approximately 20 f1I (-40 
I~ of cell paste). Determme the packed cell volume (or mass) of your samples, then substitute volumes as indicated in the 
tabk below. 
Packed Cell Volume CERI CER II NER 
10 f1I (20 mg) 100 ~I 5.5 ~I SO ~I 
20 ~1.c40 mg) 200 ~I II ~I 100 ~l 
SO ~I (lOa mg) 500 ~I 27.5 ~I 250 ~I 
100 ~I (200 mg) I ml 55 ~I 500 ~I 
MUte: All centrifugation procedures should be done at 4°C. Keep cell samples and extracts on ice. 






t·· - ~ 
r' 
1. Isolate 20 
500 x g f( 
as PBS, a 
remove tl 
page I, ru 
directly u 
50 mg tis 
2. Using a f 
3. Add 200 
-~~, ------ ~- 4. Vortex vi 
minutes. 
5. Add II ~ 
6. Vortex 5 














No .f:f. ~ow III 













I. Isolate 20 III packed cell volume (40 mg) of cells by centrifugation in a 1.5 m1 microcentrifuge tube by centrifugation at 
500 x g for 2-3 minutes. Note: If using tissue samples, cut the tissue into small pieces, add an appropriate buffer such 
as PBS, and homogenize in a tissue homogenizer. Pellet the cells by centrifugation at 500 x g for 2-3 minutes and 
remove the supernatant. Estimate the packed cell volume, add the appropriate amount of CER I according the chart on 
page I, and continue with Step 4 below. Alternatively, weigh the tissue, cut it into small pieces, dounce homogenize 
directly in CER I, and proceed to Step 4. Use a 10-fold excess of CER lover the weight of tissue (e.g. 500 "I CER I to 
50 mg tissue). In Step 5 of the protocol, use 5.5 "I of CER II per 100 ,,1 of CER I. 
2. Using a pipet, carefully remove and discard the supernatant, leaving cell pellet as dry as possible. 
3. Add 200 III of ice-cold CER I to the cell pellet. 
4. Vortex vigorously on the highest setting for IS seconds to fully resuspend the cell pellet. Incubate the tube on ice for 10 
minutes. 
_I 5. Add II III of ice-cold CER II to the tube. 
Vortex 5 seconds on the highest setting. Incubate on ice for I minute. 6. 
7. Vortex 5 seconds on the highest setting. Centrifuge the tube for 5 minutes at maximum speed in a microcentrifuge 
(16,000 x g). 
8: Immediately transfer the supernatant (cytoplasmic extract) fraction to a clean pre-chill&! tube. Place this tube on ice. 
9. Resuspend the insoluble (pellet) fraction produced in Step 7, which contains nuclei, in 100 III or ice-cold NER. 
10. Vortex on the highest setting for 15 seconds. Return the sample to ice and continue vortexing for 15 seconds every 10 
minutes, for a total of 40 minutes. 
I!. Centrifuge the tube at full speed (16,000 x g) in microcentrifuge for 10 minutes. 
12. Immediately transfer the supernatant (nuclear extract) fraction to a clean pre-chilled tube. Place on ice. 
13. Store all extracts at -80°C until use. 
Troubleshooting Guide 
Observation Possible Causes 
Low cytoplasmic protein yield Cells Tlot lysed 
Cell pellet not dispersed 
Low nuclear protein yield Cell pellet not dispersed 
Incomplete nuclei isolation 
Low concentration of protein Volumes of extraction reagents not 
appropriate for given packed cell 
volume 
No .of. ~o~ I'fotein activity detected Samples not kept cold 
.• ... f '. 
:-.: 1,.,· :' P.resence of proteases 
'')~11 ., 
Protems not compartmentalized , IncoI?pl~t~ re~oval of cytoplasmic 
... ~ " 
e:<tract· ',;' , 
Incomplete lysis ol'cells 
No or low protein yields in either Cell line dependent result 
fraction 





Micro BCA TM Protei~ Assay Reagent Kit 
SuperSignal<!l West ~co Chemiluminescent Substrate 
OPierc. Chemic.1 Co. 10/1999. Printed in the U.S.A. 
What to do 
Increase amount of CER II Reagent 
Vortex thorough Iv 
Vortex thoroughly 
Increase time of centrifugation 
following addition of CER II 
Adjust volumes as directed in protocol 
table of reagent volumes based on 
Dacked cell volume 
Centrifuge at 4°C and keep samples on 
ice between vortexing steps 
Use suggested protease inhibitor 
cocktail 
Careflllly remove all cytoplasmic 
extradt prior to nuclear lYSIS 
Increase vortexing time to be sure cell 
pellet is dispersed 
May not work with all cell hnes 
Telephone: 800-8-PIERCE (800-874-3723) or 815-968-0747 • Fax: 815-968-7316 or 800-842-5007 
Internet: http://www.piercenet.com 
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K9 #4 Protein IsolationlExtraction 
5/22/01 
Static 0 hrs--7mm total length after thawing 
Static 4 hrs--1 Omm " 
Normal 4 hrs--17mm " 
Extraphysiological 4hrs-- 12mm 
1. For static sections, approximately half of total length was used for the PI procedure. 
2. Transferred the sections to separate 50ml c~ntrifuge tubes (in ice) 
3. Added 1ml PBS to each tube. 
4. Homogenized each section 
5. At each interval, washed the homogenizer blade with D-water, isopropyl alcohol and PBS respectively 
6. Centrifuged tubes @ 1000G for 5 minutes 
7. Extracted supernatant and resuspended in 0.5ml PBS. 
8. Transferred solution to appropriately labeled 1.5ml microfuge tubes (in ice) 
9. Made 500 uL CER I solution and added 1uL benzamidine, 0.5 uL Aprotinin, 0.5 uL Leupeptin and 2.5 
uL PMSF and vortexed to mix well. 
10. Added 100uL of CER I to each microfuge tube and vortexed for 15 seconds at highest setting 
11., Incubtede for 10 minutes on ice. 
12. Added 5.5 uL of CER II to each tube. 
13. Vortexed for 5 sec, incubated for 1 minuted, vortexed again for 5 secs 
14. Centrfuged for 5 minutes at 16000Gs 
15. Labeled and put four 0.5 ml microfuge tubes into ice. 
16. Transferred the supernatanat which was the protein to 0.5 ml microfuge tubes 
17. Got about lOOuL of protein in from each tube. 
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IN-mODUCTlON 
~ prcc:edur-e has been Iaund to be the mcs: reJiabls 
oi4r=ry rn.CI"Iod h:r ~cicn at :sclubte prnrzins. Thl! 
r 'esaibed hen! is basad on Petarson's mcdilic:acicn 
,i ~ I"I'IIOthcc! and IJI:i!Q:es sodium dcdacylsu!f3ta. 
:tis J..a.Nrf Reaoenc. to laciflClca ths ~tion of 
/in3cIubl. ~I 
ant protains. en. Lowry I"'Ad:ion c::arI be n.I'I direc:Iy on 
e saiucicn. HClW'!VI!I". i'arIen!nca in the ~ Ulwry 
n I C3U5..l by c:anmcnIy used a-nic:aIs. such as Tris. 
Jl >.lliate. 8JTA. &U:::r'CIie. Ctnaa. ;rni-1Q acid S1d ~ 
!i'Ilf pher1cts. The proc:ecS.rs with pra:ain pn!ci~cn. 
'a DOC (deaxyd'1oleca) .-.d iCA [tr'chIan::Iac:c acid). 
!5 :>jJ Cl"llI5e irn:ar1enll1cQ with tile axc~dcn at phencls. 
" e etT1OU1t at venous proczins rI!CCIIered tnrougt1 tile 
It I ~p may vert depend!rg on the putioJlar ~ 
. ,-pRINC2PLE 
~e ~ ~I:a ;,,~ c:aT1pI=:s with the pl!l:JQda 
,d forms a PlJI"llIa-OIua CIllcr wne., th .. phenol l"I!5gem 
sorbence is read at i! sUtabie WCMlIengd'l b8C\N8e11 
, 1 sao nm. The prccz:in c:cncentration is detanTlined 
A...--aeon ClJrJI!. l 
FOLlN & C10CALTEU'S F'HENOL. REAGENT 
INORKING SOLUTION is prepal""l!d by a"ansf!!ning the 
CCt1I:I!ncs (18 mil ot Folin .s. CiocaIteu's Phenol ~""~ ~ 
thl! amber gta:5:1 bCCde providlld fer ena Working Solution. 
Rinse d1e Folin .s. Ciccalcau's Pnencl Reagl!f1C bat!:a wiCl"l 10 
mI daiclrmd watl!l' and add rin:sinop 11;1 Woricing Solut:icn 
bcc:!e. Add an addit:icnal 80 mI deionimd waw to tile 
Worlcino SoIutJcn bode and mix weM, St:or1! Fein .s. 
~ltI!U·. Phllt'Ol ~cag8n' WoM<ing SoM:icn ae room 
WTlPeratlJrB. 
PRCTSN STANDARc., eaa.log No. P 76.56 
~ from bovina sarum albumn. traaion V (eSAI. 
PRCTI!IN STANDARD SOWnCN, acc ~g/ml, is 
prepzred by edI:iir"g to d1e iii .. the 'lci.sma of watl!I' indicat2d 
on en. .,q ~eL Swirl gantly to com!lll!!2ly dissolve. 9c:re 
scluticn in tha refngeratct' (Q..5°CJ or free=- [below O°C]. 




(Without Protein PMlcipiacion) * 1. Precare STANDARO TUBES by diuOng P"'teIf1 Standard -e. SOlution with watV' to • volume of 1.0 mI in ac~at:Iy 
--~liloaJed taSC woes: 
C; Jlrvc...." . Pf"ocai_ 
n~ Sbn4 ..... Soh.cion W.C'IM' Caftcana-.cion 
Ye.et (",II ( .... 1 (,,'-",",1 
-----..,-e-A-G-e-N-TS-------- ~ I 0.125 0.S75 50 
" %. 0.250 0.750 100 
(For laboratory use only. , 0.500 0.500 2CO 
r--: for drug, household or other uses.) -"\ Q.750 0.250 ::mo 
S 1.000 a 400 
. REAGENT, MOOIFlED. catalog No. L 1013 
" COI=lI=lDSIVE. Avoid concaa wiCh eye". skIn 
,i . 00 noe braaCl"le dusl:. 
~ REAGCNT SOLUnON Is prepared by addln<;l 40 
vater to • bottle at lJ:Nvry ~agent. Modified. Mix well 
wom:ing to ccmplea:1y dine ..... 00 not sI1e~ "0 os to 
n ! roaming. Solution i. scabkl _~ room t2mperawra. 
~ r REFI=l1GERATE. 
lLUTION, C=log No. 0 5525 
!OUlO solution at sodium deoxyc:l101ace. 1.5 mglml. 
C :JACETlC ACIO'SownON (TeAl, 
1\ i 4396 
aus SOlutiorl.of tric/1toroec:atic acid, 72% w/v. 
~: COARDSIVE. CAUSES BURNS. Avoid ccnc.ac: WlcJ1 
_" ;d domino. . 
!i~10CALTEU'S PHENOL REAGE1\IT, 
Na..F 9252 
1: COMOSlvE. CAUSES BURNS. A\IOid ccn= wi~ 
ii-'Id l:luLhRlQ. 'Do 'no~ bniiJch" vnpcr. _ ' ". . 
\ 2. l...!Il::el 0 = tube SLANK ond odd 1.0 mI wc= 
-5( ).l. 3. Add 3ampJe to appropne~ labeled CZ5t wbe end d'ua: to 
7
,,, - 1.0 ml wn:n w.~r. 
'\i 4. Add 1.0 ml Uiwry Reagenc SOlution to STANOARD. 2LANK 
and S~~!'LE tuoes. MIX well. 
5. Alk;w solutions to ~cand ~ mom cunperacure Fer- 20 
mIflUO:s. 
6. Wi~ nlpid and immedi.C2 mixing. add 0.5 ml Falin &. 
Cl<:x::alC2u -s Phenol Reagenc Workin<;l Soluaon to each cube. 
7. Allow COlor to develop lor 30 m\l1Utes. 
8. Transfer sotucons to cuvetS and measure Che absorbance 
0/ ~e STANDARDS and SAMPLE ClJbe~ v:s. the 8LANK at 
e """"eleng~ becween ::00 ,nd 800 nrn. Complete reading. 
witllin 30 minutes. 
9. Ploe CI1e absorbance values of cJ1e STANDARDS lIS. theIr 
corr-..socndrtg proC<:tn concentl'"'OCJCn& to prep~ c caJib,-"ccn 
0JrVa. (See Figurq 1 lor a typical calibration cu~e for 
.~ndards ac 750 nm. J 
10. Oetermne i:/1e proteIn concentration of ~e SAMPLE 0 
(rom the eaijb",tion curve. MuJ6p1y ~" result bit 
apcropnoce dtlJticn fcc::cr to obCllin the protein c:on::er 
in ttle original sample. 
____ .A-"- ...... , ....... J-.~ · ... L i..a. •• : ~~~,..- .:1. ~~ ... ...,.,. .-
" "' . i ~ .,' . ," 
- , , 
_____ -1 













- __ ---t----- ---- - -- __ .. --. . _,_. --_ ... - ...... - - -----_.-. 
_ .. -- ... -_. - - - -'. ... - - •. .. - .. . 
-1 ----t--- ----- ----
-- ---- ---
--r----------~ -- --- -- ----- - ----r---------_____ ~ ______ ---------. - -. __ - - .-
,-
--- ---- •.. _-_._--- - ."- - ".-------- •. -.-... - - -.- - .......... -"-'" --------------_.---.------- -.-------
... ----.---. --_.-_. --------... "--_ .. _-.- - ----." -- --._-" ------------------------- --- ------------, 
~
' HI'l!:,----=1_' _J:L32ec--_____________ _ 
;1
1
' ~ \h.SJ....-l4___ ._. ______ . ___________ . __ ._. _______ . __ .. _ 
i ~ I 
~~ ",ji-llll.~. __ j~ __ ~)-..i1.Li'--~O.::::...----- __ _ 
----.----"- --------- --------L---1 
------------- _ ... _-------- _._ .. -
;: £-t __ 'd~t.-l£..:\l_____ . __ ._. _____ ._ .. ______________ _ 
,1 Su_ 8_':120 _____ '--'--- --. - --- - - - -- .. - ------- ---- .--- -----.- -. 
': (". .\ {- S).J ____ .\L~ ___ .... _ .. ___ .. _. _____ . _____ . ___ . _________ .. ____ ._._ .. _________ ... _. __ _ 
------_ ... _----_. __ ._. __ ._--_._---_. _. ----
~:.__ liP • _ A..~~..... ... ~. ............_.~ u ~ ~ ~~, '-" ,... . '*".; ~ oJ .... "...., -
, ''!: 1. • I' - t I 
\ 
7 
. ___ . _______ ___ ... ___ ~~ur.t·)---~!/(11 
L-.----------- . t'.<'-"""'- ,...~ c.L~ ___ . 
L--,,<~~Lc;..~-o.~e...-£,~~-~ . .1-:-- ,~dc;(_I~_~~Qj~~-±:h.L<,L-~,~,-lc-=r-'lLJ'lDJ. -..I-Cl,be.,J\~~L c,.l.!,:,f.\:-_~ "L h _+-..:...":IL)-_. __ 
--_-l~-"l.:O::;.<'--..:...-'-''-'.:.!.-'--'''-.,u \b_J:sI"::'L':.~U1:~ a .. rLf-±:.!=..LL£f~"..I<-_~----:"'-1.)_. ---.----.- ----.. -
...s_£.[,-.;,f.~.L_~b ,,0. ___ (_~~: tv' e. ~ ___ _ 
-h_---. ..,.------=w.::..., ... ..Q...I------00 A..j ___ .f,"" <;"S.L... ------.----.----.---... 
---a:~ ____ .. ~~.Y.\J~_ ~~).s_b..~.wNe4tfCet l~. __ ( (Y\uSI.-'-~~C_ __ ..JL0...!.h_....:rfL~0-- _. - -------. 
... " .. - .... 
:":~.i:··:: '0/: .. ': :.' 
_0 __ 0 •••• ... .... ..... . 














..... ... .. .. .. .. ... 
~.: !: :-. 
"" " .. .. .. .. - .. 
0 .. :: :.':: 
.0 ..... 0 ............ 
... 1 ' .. :' .. : 
.. .... _-
...... .. .. - ... 
....... - . - --
---r---------.- -_. -. - .-- . -. ._'- .. -
.: ,-. ~~ ~.~: 
.. .. ..... ------
~·7~~~ .. .. ... .. .. 
.... --
.... ...: 1'-' 
'-I). 10'1 ML 
.. :: :: :-: ~ . 
: .. :-:-:!.: l1.J·'5 - ......... 
- . - ... 
... ~ .... :.~ 
'_' :: :: '_' &,0 ~ (1':' 
- d ~~::: ........... ........... 
... ::' ::: 
. ...... . - - . - -- 1.70(,: 
'-.- (c..Of,t-.) 
---- --. - - --l'-;~------------------- --e&-<-i". \' \ ;~ ------
- ~----
1. i;j ?, st-..vJ"',,~J 
...rc!.L- -----r--J 
-t,~ 













........ - .. --.. 
"" .... .... -_ .. 
... :: :.,,: 
.0 ... "0 - .. .. .. -
... ':'.!'.! ..... 





" ...... . ------
, , · .... o .. __  
... 0::: " 
· '-.,. · ........ . - ..... - .. 
I':: I' :.': · . ... . ... .. ... , ... 
:: ~. ~ :-: 
· -10. " • . .. . .. .. . .... .... --
"IL, le'1 M.l 





----- - -------- 5/ & oLo _....:I_~ ___________ .~ __ " _____________ ___ _ ---- ------- --!. 
'i._(i0_2Lil-~~_~~\L_~<I'v{. t'~ Le..-c-~<&£\tr~t~_!9 __ ....:)~ __ JD=.lL~-yry_\..._o.Y\-~ j.~r:9t.l-,----
g -C:~'(\,Oet*_<oJ\'S!J __________________ . ______________ . ____________ _ 
_______________ JJ.s.L.~-~~vro~l\-~r~.£c.:'~--tJi~c-))-------_______ _ 
/ 
" _____________________ J:ub 3~~\Li"l~--lllYvvJ--t~~} ~ ___ :+~""..; _____________________________ _ 
5~~c!g-,.,..rt\, _______________________________________________________________ --------JI----" 
-----------------------
-- ----- - ---1----
InHtil------------------------------------------------- -------------- ---------_-I-_ILJ 
---I-_\/._ 
IiIIlP'::lll1l1~·~I ___________________________ _ 
----- ------------- --- --- -----If----"1 
1'tJ---------------- ---- --- ----- -------- -- --------------------- -----
---- ----- --------
--------- ---- - ------- ---------
------------------- ---------- - --
1L:'----------------------------------------- --- --------- ---------------- __ -________ _ 
------------ - -------- -- ------------ ------ ------- -
___ ~o..i{L 
---~!..J_--~2l__l~-~=:...J.---------------- ----- ---------------- ---
-------------- ---- ------- -------
---------------------- --- - -- ----, 
---------------------------------
----i±--'--"--'--,~L>__""'~_=_=_ __ _'___='_"!cC__. _____________ ----------------------------------------_____ 11 
----r----''''-'--'''--VJ=,,'-'--_'--'--'-__ -'_ ....... ____ '-'~ __ {\<_.J "--0--- ---- -- -- --- ----
---------t----5./..:k.I:f)lt--- .---- --:-- ~---
___ H :L lfNJ? 
h I 4 lif =-----t----'--,,------- --- -----------
---1"---------------- - ---
--------1 _______ - - --- -.--------
-------.-r----.------.---------- .--- ----- ---




!f.!!I!!,,.. /-ef:" tt /1;f ~i. .. .. ... _ _ 
.-,: : :. : : ""':" "':' ~. : ... :- l' : ::- .................... : to;: :.' ••••• :_'. :.:: ~:....: :.~: : : ' .... , - -
':. '-': :: : : .:. : : : : .:. '::.. ...... - . .. - .. 




.:; ,-. : 
... :.~:.l:-, 
.0 ...... . .. .. .... .. 
: : .. 
';:~q ..... .. . 
::: ~.~ f-. :~ · ....... . .. .. .. _ .. 
i f-:::: · ...... . 
.... --... . ... · . ... . .. .. .. .... .. 
.. ... .. .. ... 





'_' : .~: ~ ~:~ t: 
-:.": :...  .:::.. : .. : .. ...... . ... -.. _-
~ ' .. : 1 :...: . ..... . . _ .. ----
-'-::1 '-:C'-:= . -... . . ..... .,. -- . __ . 
::l :~:-:':: 
..... 
...... 0 ••• .. .. .. .. .. .. 
:::..::' : 
~ . : 
- ...... 
. . .. /~: :~;'1 ............ 
?::~? 
















































- • ~ < 














":"'1 -  
.0 ...... . 















0_' ::.... : 0 .. " 
...... I •• .. .. .. .. .. 
... . _ .. ... . ... "oo •••• .......... 
· , ...... . .. .. .. .. .. 
· . .. .. . .... .. _-
· ....... . .. .. .. .. .. 
., .. .... . .. . .. .. .. 
:"!:1 :..,: 
" .. 0 '." : _' :_. 
j~.~o~: . 4:~4~: S'-I.(;'O .. ....... 
. : .~ ~ .. :.. \ ") 
r ,d .;:.;..: ::.: ... '1 J ,J"I_ .• __ _ 
... ·_·;(I.ul 
~~ ~:: .~: J <J'. 7:l. : :.: . ~: ~-~~: :(~. 07 .. . .. .. - .. .. . .. - .. 
U, C's\ ---------- -- -- -----.. 1----""-""-"-- "---- -----" ----- --C] -"-\:Zj-"- " "- ----" "-- --- ------..I 
--"-"----"---11--
~--- ----- --- ------I--t...=I---II~,__=l 
--- ------------- -------"'-11-,-,---8----
-" ---'(TI-"-- ---- ---""- - --""- "- --" ---""---" -- ------- "-"---I _ 
11I11r11'-----------------L.~~~------oI- ""- -- --"----------- - "-"-"--"-"-------4 __ 
-------------------L-_ 
__ (~ - <6 !de.,\\61 ___________ " -------"---"----l-_ 
Wc.:> h PBS S ('I): 
M-____________ ,I----'~-"o.-cl-d-g~~ " a.n+;~e:h-l~\[c.J _J,_O~{f)~;'_'__ _ __l_ 
-
~--------------t-->...,;:;.<_ __ ~~J~S W~h '5 ~~-' ---- -" - -"------l---
"BLDJkL-w~e,t<L-O \od:: Ll_O_("\_~~-t--'-"'- ~ -~4d-fKcrte:,LL_blQ~_I;, ___ ~..\Q_ (Y\ ~6)_ _ _ __ " _____ " ____ _ 
~iID o.cL~~\\S-U6-Lhc-- ~ __ J~ __ 1:t~J __ Ab ____ ~ __ r Lh,=-"_ 
I 
" ___ " _____ '1 __ -" __ -_ - _J: QO ___ "Jo_~D_5 ________ " __ _ 
1c-------____ \~1L_tP_ ""'-'-'---=cd.:_" _____ I ______ " ______ L tU--±~ _~eJ-' --:ra"----_ --- +---
" ______ L12"~_+o" __ ~JL2?_ " __ _ " __ J~~_~Q" _JO __ U,Le.,\L , _____________ """ " __ "" ________ _ 
_ _ ""_" ____ L:}_(',pf\+~_\_I,A)~_I\ 4 __ _ " J--) ___ C9'0!fo ("_~eJL<z __ " ___ "" __ " ___ "_ " __ 
wa.s h P 5':J 5 (Y'\ ; f\ 
-----Ir-~"~- -"--"- -"----"--" - --""----- --- -- --_______ "_" ____ """ ____ ">-_ 
9~~~~_b~Lilll:J _____ ,""""'_"" A".+:"rf'Ou":& ___ ~~_~b ___ L-_i0} ___ 3Q "(Y\;-f\-, ______ " __ " ____ """ ____ " __ ~_" 
'36 ~;<"I, 
------------/--------"-------------"----" ""- ""-----"------"- "-~--
11--- ---"-"--- ---- ----- ----------- ------ ------------- --- ~-
1-----------------" -"---- -- --.----•• ---_._-- -.------- •• - ___________ 4 _._ .. __ • _____ _____ 
\----- -"------ ---"----------"---""-- -""-"--
\------------------ ---------"----- -" -- ----------- --"--""----"-"---"- "-- --- ------k __ _ 
Ob - \2 - 01 
~'":.:"".~.~ .. 
-----Page-lof2---- -----
PRODUcr SPECIFICATION SHEET 
HUMAN F1BRONECTIN 
Fibronectin is a broad range natural cell adhesion factor. It is a 440-500 kDa dimeric glycoprotein consisting of two 
similar 220-250 kDa subllDits linked by two disulfide bonds. It is found as a dimer in plasma and in multimeric form 
in the exttacellular matrix and on cell surfaces. Its primary function is related to cell adhesion to the extracellular 
matrix which OCCUD via the Arg-Gly-Asp-Scr (RGDS) seqUCllCe of fibroncctin with the appropriate transmembrane 
integrin receptor of the cells. I Other domains of fibroncctin are also involved with this adhesion process and may 
involve inrer.u:tion with collagen. heparin and other cell surface glycosaminoglycans. ' The conformation and 
orientation of ad!orbed fibroocctin is also important and bas an effect on cell spreading and strength of adhesion of 
_____ ~';;""-'-________ ~cnd~oth!,!!!!!e~lial~ce~lls~.l~Fib:.!!1 ~ro~nec~ttnYl· '7"addi",:",·u"",·on_(lLserum..free medium pmmorcs cell adhesion 3 More significant effects..are'--___ _ 
observed with BIlK. CHO and other cell lines by coating of culll1reWare with fibroocctin at 1-S ug/crrt. Details of 
- ------1""-----
, 
fibronectin sttucture, properties, distribution, cellular expression, interaction with other proteins, matrix properties, 
cell interactions and adhesion and effects on differentiation can be found in two excellent boola by Hynes or 













3S4008 LOT NUMBER: 001760 
Human plasma' 
NOI'E: The soun:e pJagoa WIIS tested and found IIOI1I'I!Sdive for hepatitis B 
surface antigen (HB.Ag) and negative for antibody to human 
immunodeficiency- "!'InJS (HIV). Nevertheless, this product should be 
handled using the s:une saCety precalittcm, used when handling potentially 
iDfectJous material. 
1 milligram per vial, Iyopbilized. 
100 mM CAPS, O.ISM NaCl, 1 mM calcium chloride, pH 11.0. 
Equilibrate vial to room temperature. Resuspend in one milliliter sterile distilled 
water. Allow 30 minutes for material to go into solution. DO NOT AGITATE 
OR SWIRL. If entire amount of material is not to be used immediately, 
transfer into appropriate aliquots and store at -2O"C. It is recommended that 
solubilized product is used within two weeks. DO NOT STORE IN FROST-
FREE FREEZER. AVOID MULTIPLE FREEZE THAWS. 
Human Fibronectin is genera1ly used in the concentration range of 1-5 
micrograms per eml of growth surface for attachment or at 5 micrograms per ml 
as a me'dia additive. 
Please see reverse for coating directions. 
440,000 in non-reduced form. 
Bec:tan Dickinson Labware 
Two Oak Pat!< 
Bedklrd, MA 01730 
(781) 275.axJ4 Fax: (781) 275-0043 
(800) 343-2035 
'~-. -.::';'::" .. ::~~:--:::~.~. ":.::_::"_. , ....... !!:U',..:.-:--.A.~._ .. --.,..."... __ . __ _ 
~_.~ . .O..+:.::...- •.. ' 










Page 2 of2 
QUAliTY CONTROL: L. 99% by 4-12% SDS-PAGE under reducing conditiollS. 
Human Fibronectin has been tested for its ability to promote attachment and 
spreading using BHK-21 cells. 
Fibronectin bas been tested and foUlld negative for the presence of bacteria, fungi 
and mycoplasma. 
STABn.ITY: Stable for a minimum of 3 months from day of shipment when stored at 2-8°C. 
REFERENCES: 1. Aota, S., et.a1., 1. BioI. Chern., 266:15938 (1991). 
3. Barnes, D., and Sato, G., Cell, 22:649 (1980). 
4. Hynes, R.O., Fibronectins, Springer-Verlag, New York (1990). 
5. Mosher, D.F. (ed), Fibrom:ttin, Academic Press, New York (1989). 
Coating Procedure 







Dilure fibroncctin to desired concelllrarion using serum-free culture ea++, Mg++ free medium or buffer 
at pH 7-9. The final solution should be sufficicn!ly dilure so that the volume added will cover the surface 
evenly. 
Example: If the final coating concentration will be 5 uglcm1, dilute the matei13.I to 50 uglml and add I 
ml/35 mm dish, 3 mU60 mm dish, etc. 
NOTE: Because of the CAPS component in the HFN preparation. buffers of media containing ea ++ 
andIor Mg++ added to J!ie HFN may result in the formation of insoluble metal hydroxides. This will not 
occur if the buffering capacity of the diluent brings the pH to 8.0 or lower. 
Add appropriate amount of diluted fibronectin to culture surface. 
Incubate at room temperature for I hour. 
Aspirate remaining material. 
Rinse plates carefully with dH10 - avoid scraping bottom surface. 
Plates are ready for use. They may also be stored at 2-8"C damp or air dried if sterility is maintained. 
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
354008 rev 1.0 Release Date: 5/14/99 LOT NUMBER: 001760 
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SOP University of Tennessee Page 
Number . Medical Center 
Vascular Research Lab lof3 
VRL-SOP.307 
Standard Operating Procedures 
Title: H&E staining of paraffin embedded tissue slides 
I. Scope: 
This SOP will be followed by personnel engaged in research and clinical studies in 
the Vascular Research Laboratory of the Department of Surgery. 
II. Purpose: 
To describe the procedures for regressive hematoxylin and eosin histochemical 






a. 1 % acid alcohol 
b. Ammonia water 
c. Working eosin sofiition 
d. Hematoxylin stain 
e, 100% ethanol 
f. 95% ethanol 
g. Xylene (or equivalent) 
Equipment required 
a. Solution containers (staining boats). 
b. Multi-well slide staining station. 
c. Exhaust fume hood. 
Protocol Guidelines 
a. Deparaffinize and hydrate tissue to deionized H20 (VRL.SOP. ) 
b, Stain in Richard-Allen IT hematoxylin for I minute at room temperature 
(RT). (Harris hematoxylin substituted for 12 minutes at RT is an acceptable 
substitution) 
c. Rinse in tap water until glass is clear. 
d, Differentiate by dipping 5-10 times in 1% acid alcohol. 
e. PI,ace in ammonia water to blue. «10 sec) 
f. Rinse in warm running water for 30 sec. 
g, Place in 80 % Alcohol for I min. 
h, Place in 1 % working eosin for 30 sec . 
i. Serially place in 3 changes of 95 % Alcohol for 30 sec each change. 
j. Place in absolute alcohol for I min. 
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Standard Operating Procedures 
k. Clear in 3 changes of Xylene for 2 min each change. 
\. Coverslip with Pennount and coverslip in fume hood. 
Expected results 
a. Nuclei stain blue 
b. Erythrocytes stain reddish pink 
c. Cytoplasm stains pink 
Calibration Instructions 
Study pathologist will approve acceptability of staining quality 
Routine Reagents needed for working reagents solutions 
a. Deionized H2O 
b. 100 % ethanol 
c. Ammonium hydroxide (VRL.SOP.20 ) 
d. Stock eosin solution (VRL.SOP.20 ) 
7. Routine working solution maintenance 
a. Alcohol station solutions should be changed every twenty-one days 
b. Ammonia water station solutions should be changed after 5 uses. 
c. Hematoxylin solution should be filtered every third day or if 
crystallization is observed. 
8. Trouble shooting 
a. Hematoxyli~ solution contains crystals: filter hematoxylin using FisherR 
filter paper. 
9. 
b. Nuclear staining is too intense: incrementally increase differentiating in 
acid alcohol solution. • 
c. Nuclear staining is too pale: incrementally increase hematoxylin stain~ng 
time. 
d. Cytoplasmic staining is too intense. Incrementally decrease staining time 
in eosin working solution. 
e. ' Substitution of this procedure by automated staining (subcontracted 
outside lab) is acceptable. 
Responsible person(s) 
Laboratory director / laboratory supervisor 
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Carson, FL. Hu;tol:ecltmc)l,O,gy:. a self instructional text. ASCP Press. Chicago, 1990 
V. Attachments 
NA. 
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VRL .. SOP .. 607 
Standard Operating Procedures 
Title: Cell Counting with a Hemocytometer 
I. Scope: 
This SOP will be followe<l by personnel engaged in research and clinical studies in 
the Vascular Research Laboratory of the Department of Surgery. 
II. Purpose: 
To describe the procedures for counting cells with a hemocytometer. 
III. Procedures: 
1. Reagents Required 
2 . 
3. 
a. All (\':agents used to split cells (refer to VRL.SOP.601) 
b. Trypan Blue 
Equipment required 
a. All equipment required to split cells (refer to VRL.SOP.601) 
b. Hemocytometer, cover slips 
Operation Guidelines 
a. Follow steps 3a .. 31 from cell splitting procedure (refer to VRL.SOP.601) 
b. Resuspend cells in one ml of media. 
c. In a 1.5ml tube, add 500lli Trypan Blue, 475111 of C:MF and 25111 of the 
media. 
d. Dry hemacytometer ant! place coverslip on top. 
e. Add approximately 20 III of suspension into both sides of hemacytometer. 
f. Calculate the cell count using the equation: cells/ml = (n) x 104 , 
where n = the average cell count per s~uare of the four comer squares 
counted. For example: cells/ml = (n) x 10 or cells/ml = 30 x 10,000 = 
300,000 cells/ml. 
g. Cells that land On the outside the lines, do not count. All cells on the 
inside of lines count. 
h. Cells that take up the blue color are dead and they do not count. 
4. Trouble shooting 
Same as VRL.SOP.601 
-----t'---- --- ------_._-_._--
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Standard Operating Procedures 
5. Calibration Instructions 
NA 
6. Routine Reagent 
NA 
7. Responsible person(s) 
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V ecto~ Red Alkaline Phosphatase Substrate Kit I 
Cat. No. SK·5100 
The Vectofl' Red substrate kit contains all of the reagents necessary (except buffer) to prepare 
solution for either immunocytochemical or membrane-based applications. Vectoril Red 
reaction product that can be seen using either brightfield or fluorescent microscopy. V 
permanently mounted in non-aqueous media or mounted aqueously in VECTASHIELDiI 
DISPENSING REAGENTS: 
For convenience, the reagents are supplied in dropper bottles. When dispensing drops, hold 
inverted vertical position and squeeze gently. To prevent evaporation, secure the opaque 
when they are not in use. DO NOT PIPET REAGENTS DIRECTLY FROM BOTTLES. 
each component may be different due to solvent characteristics. Proper concentrations of 
components in the working solution are assured only by using the drop dispensers. 
INSTRUCTIONS FOR USE: 
Prepare the Vectofl' Red substrate working solution immediaJely before use. 
1. To 5 ml of 100 mM Tris-HCI, pH 8.2 - 8.5 buffer*, add 2 drops of Reagent 1. 
2. Add 2 drops of Reagent 2 and mix well. 
3. Add 2 drops of Reagent 3 and mix well. 
* This kit contains a modified formulation to improve stability. It is important to make 
solution in 100 mM - 200 mM Tris-HCI buffer, pH 8.2 - pH 8.5 
Incubate tissue sections or membranes with substrate solution at room temperature until 
develops. Development times should be determined by the investigator but generally 
provides good staining intensity. Improved staining may be obtained by developing the 
Wash sections in assay buffer for 5 minutes. Rinse in water. 
For permanent mounting: Rinse in tap water, counterstain, if desired (see chart on reverse), 
and mount in a permanent mounting mediwn, such as VectaMount -, Catalog No. H-5000. 
For aqueous mounting in VECTASHIELDiI Mounting Medium: Tap excess buffer frn".,...' ..... ,Nn' 
Before mounting, slides may be rinsed for 2-5 minutes in 100% ethanol to increase the 
Red fluorescence. 
The Vectofl' Red reaction product is a highly fluorescent, non-fading, bright red nr •• ,.;,.,,;tOlr .. 
with Texas Redil or rhodamine excitaU(;m and emission filter systems. Vectoril Red fluore:scc~[ 
visible with fluorescein or AMCA filter systems using broad band emission filters. 
NOTES: 
I. Use the working solution of Vectoril Red within 15 minutes of preparation or delcreas~~ 
result. Increasing the incubation time in substrate solution beyond 45 minutes will not 
sensitivity, unless freshly made substrate solution is reapplied to sections. 
2. Do not heat Vectofl' Red substrate kit components or working solution. Heating decreases 
3. The reagents should be stored at 4°C and protected from light whenever possible. 
precipitate may form in some reagents upon prolonged storage. This will have no effect 
or intensity of the staining. Do not fi~ter the reagents or working solution. 
4. Do not put sodium azide in the buffer used for the Vector ll Red working solution; it will 
5. For tissue, using 0.1 % Tween II 20 in the VectoJ'l' Red working solution may increase the 
crispness of staining especially when non-enzymatic ~ntigen retrieval methods are used 
staining protocol. Tweenll 20 should not be added to the Vectoril Red substrate solution 
applications. 
6. When using neural tissue, Vectoril Red is not recommended for visualizing processes, 
(inadequate staining may occur). 
7. Endogenous alkaline phosphatase activity (other than the intestinal isoenzyme) can be 
addition of levamisole (Cat. No. SP-5000) to the buffer prior to the preparation of the 
Intestinal alkaline phosphatase activity can be inhibited, before immunostaining, with 
pretreatments (Bulman AS and Heyderman E; J. Clin. Pathol. 34, 1349-1351,1981). 
IMPORTANT: Little is known about the toxicity and carcinogenicity of the substrate 
Care should be taken in the handling and disposing of all the reagents. 
TWfd* 20 u a relUI."d 1r1Jde,"",* of AI"" Chcmicallrulwtries 
Tc.mr R." II G rc,ut,red""'''''''' 0/ MDlcculdT Probe! 1M. 
Vector Laboratorie~ ... JDP., 30 Ingold Road, Buriingame, CA 94010 U.S.A., • (650) 697-3600 •. 
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Cat. No. SP-SOOO 
Levamisole will inhibit most forms of alkaline phosphatase other than the intestinal isoenzyme. 
Since the intestinal form of the enzyme is used as the marker enzyme in the VECTASTAIN® 
ABC-AP Kit, levamisole can be used to inhibit endogenous alkaline phosphatase in most cases. 
Because the inhibition produced by levamisole is reversiblerthe inhibitor must be added to the 
substrate solution. 
This lot of levamisoie was tested on two frozen tissues and was found to completely 
inhibit endogenous alkaline phosphatase activity. 
INSTRUCTIONS FOR USE: 
When used in conjunction with Vector Laboratories' Alkaline Phosphatase Substrate Kits, add 
one drop of Levamisole solution to 5 ml of alkaline phosphatase substrate buffer and mix well. 
Then add substrate reagents and continue as outlined in the instructions for the Alkaline 
Phosphatase Substrate Kit. 
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Vector Laboratories [vector@vectorlabs.com] 
Thursday, July 26, 2001 3:20 PM 
. Donnell, Robert L. 
Re: Vector Red Excitation and Emission Levels 
Thanks for your email and phone inquiry from Frances Kirkland. The 
existosgpn is broad and ~eems to be from iiPpm EhriUSh to i69ii' The 




----- Original Message 
From: "Donnell, Robert L." <RDonnell@mc.utmck.edu> 
To: <vector@vectorlabs.com> 
Sent: Thursday, July 26, 2991 11:35 AM 
Subject: Vector Red Excitation and Emission Levels 
> We currently use your Vector Red Alkaline Phosphatase Substrate Kit 
and 
are 
> wondering what the excitation and emission wavelengths on the Vector 
Red 
> Stain are. 
> Sincerely, 
> 
> Robert L. Donnell, DVM, PhD 
> Director of Surgical Research 
> Department of Surgery, UTMCK 
> rdonnell@mc.utmck.edu 
> (865) 544-9774 
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File: FIB/SMC 8/3/01.001 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Histogram Statistics 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 4730 
Marker Left. Right Events % Gated % Total Mean PeakCh 
All 1. 9910 
M1 1. 132 
M2 132. 8582 
File: FIB/SMC 8/3/01.001 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
4730 100.00 94.60 74.74 
4221 89.24 84.42 49.88 





Sample 10: FIBROBLAST VECTOR RED 
Ac:guisition Date: 3-Aug-1 
Gated Events: 4730 
Marker Left. Right Events % Gated % Total Mean Peak Ch 
All 1. 9910 4730 100.00 94.60 84.97 42 
M1 1. 132 4104 86.77 82.08 50.87 42 
M2 132. 8582 634 13.40 12.68 306.27 198 
Histogram Statistics 
File: FIB/SMC 8/3/01.001 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: :rAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G1 Gated Events: 4730 
Total Events: 5000 
Marker Left. Right Events % Gated % Total -Mean PeakCh 
All 1. 9910 4730 100.00 94.60 73.68 27 
M1 1. 132 4162 87.99 83.24 43.92 27 
M2 132. 8582 573 12.11 11.46 290.61 139 
Page 1 
""U'--' M'- "u.....101 K-:"l' 
ro..bb'\t ~\b(oblO-.sb 















































File: FIB/SMC 8/3/01.002 
Patient 10: T AG= TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 4548 
Events % Gated % Total Mean 
4548 100.00 90.96 97.73 
3782 83.16 75.64 61.34 






File: FIB/SMC 8/3/01.002 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: T AG= TUBE A~uisition Date: 3-Aug-1 
Gate: G1 Gated Events: 4548 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 4548 100.00 90.96 116.37 61 
M1 1, 132 3603 79.22 72.06 64.43 61 
M2 132, 8582 955 21.00 19.10 312.50 137 
Histogram Statistics 
File: FIB/SMC 8/3/01.002 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: 'TAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G1 Gated Events: 4548 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 4548 100.00 90.96 98.14 40 
M1 1, 132 3779 83.09 75.58 53.88 40 
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File: FIB/SMC 8/3/01.003 
Patient ID: T AG= TUBE 
Gate: G1 
Total Events: 750 
Histogram Statistics 
Sample ID: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 462 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
File: FIB/SMC 8/3/01.003 
Patient ID: T AG= TUBE 
Gate: G1 
Total Events: 750 
462 100.00 61.60 473.44 58 
313 67.75 41.73 57.05 58 
149 32.25 19.87 1348.13 150 
Histogram Statistics 
Sample ID: FIBROBLAST VECTOR RED 
A~uisition Date: 3-Aug-1 
Gated Events: 462 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
File: FIB/SMC 8/3/01.003 
Patient ID: lfAG=TUBE 
Gate: G1 
Total Events: 750 
462 100.00 61.60 476.76 
310 67.10 41.33 55.94 





Sample ID: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 462 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 462 100.00 61.60 383.66 13 
M1 1, 132 324 70.13 43.20 43.01 13 
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File: FIB/SMC 8/3/01.004 
Patient 10: TAG= TUBE 
Gate: Gl 
Total Events: 720 
Histogram Statistics 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-l 
Gated Events: 360 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 
Ml 1, 132 
M2 132, 8582 
File: FIB/SMC 8/3/01.004 
Patient 10: TAG= TUBE 
Gate: Gl 
Total Events: 720 





49.44 24.72 52.28 
50.28 25.14 1424.69 
Histogram Statistics 
Sample ID: FIBROBLAST VECTOR RED 
A£.quisition Date: 3-Aug-l 
Gated Events: 360 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 360 100.00 50.00 813.38 743 
Ml 1, 132 176 48.89 24.44 54.67 27 
M2 132, 8582 184 51.11 25.56 1539.10 743 
Histogram Statistics 
File: FIB/SMC 8/3/01.004 Sample ID: FIBROBLAST VECTOR RED 
Patient ID: ./fAG= TUBE Acquisition Date: 3-Aug-l 
Gate: Gl Gated Events: 360 
Total Events: 720 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 360 100.00 50.00 690.35 21 
Ml 1, 132 187 51.94 25.97 43.71 21 
M2 132, 8582 173 48.06 24.03 1389.31 813 
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File: FIB/SMC 8/3/01.005 
Patient 10: TAG= TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 3740 
Events % Gated % Total Mean 
3740 100.00 74.80 2073.54 
418 11.18 8.36 46.06 






File: FIB/SMC 8/3/01.005 
Patient 10: T AG= TUB E 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
A~uisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 3740 
Events % Gated % Total Mean 
3740 100.00 74.80 2042.56 
416 11.12 8.32 44.93 






File: FIB/SMC 8/3/01.005 
Patient ID: lfAG= TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 





Gated Events: 3740 
% Gated % Total Mean 
100.00 74.80 1703.18 
12.54 9.38 37.92 
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Histogram Statistics 
File: FIB/SMC 8/3/01.006 
Patient 10: TAG=TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 2785 
Events % Gated % Total Mean 
2785 100.00 55.70 1129.67 
599 
2186 
21.51 11.98 48.53 






File: FIB/SMC 8/3/01.006 
Patient 10: T AG= TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
A£.quisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 























File: FIB/SMC 8/3/01.006 
Patient 10: 'T AG= TUB E 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 2785 
Events % Gated % Total Mean 
2785 100.00 55.70 1318.56 
407 14.61 8.14 77.28 






LV",';'f{ 0 \ 
SM(" \.\vS('(\c..'? .. 
















































File: FIB/SMC 8/3/01.007 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Histogram Statistics 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 3766 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 3766 100.00 75.32 90.53 54 
M1 1, 132 3218 85.45 64.36 57.86 54 
M2 132, 8582 558 14.82 11.16 279.69 136 
Histogram Statistics 
File: FIB/SMC 8/3/01.007 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: T AG= TUBE A~uisition Date: 3-Aug-1 
Gate: G1 Gated Events: 3766 
Total Events: 5000 
Marker Left, Right Events "10 Gated "10 Total Mean PeakCh 
All 1, 9910 3766 100.00 75.32 80.35 50 
M1 1, 132 3355 89.09 67.10 54.73 50 
M2 132, 8582 418 11.10 8.36 286.82 141 
Histogram Statistics 
File: FIB/SMC 8/3/01.007 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: 'fAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G1 Gated Events: 3766 
Total Events: 5000 
Marker Left, Right Events "10 Gated % Total Mean PeakCh 
All 1, 9910 3766 100.00 75.32 53.28 38 
M1 1, 132 3544 94.11 70.88 39.06 38 
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File: FIB/SMC 8/3/01.008 
Patient ID: T AG= TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 4648 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4648 100.00 92.96 228.75 66 
M1 1, 132 2295 49.38 45.90 76.34 66 
M2 132, 8582 2368 50.95 47.36 372.01 138 
Histogram Statistics 
File: FIB/SMC 8/3/01.008 
Patient ID: TAG= TUBE 
Gate: G1 
Sample ID: FIBROBLAST VECTOR RED 
A~quisition Date: 3-Aug-1 
Gated Events: 4648 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4648 100.00 92.96 247.50 181 
M1 1, 132 1822 39.20 36.44 87.59 123 
M2 132, 8582 2841 61.12 56.82 349.54 181 
Histogram Statistics 
File: FIB/SMC 8/3/01.008 
Patient ID: 'fAG= TUBE 
Gate: G1 
Sample ID: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 4648 
Events % Gated % Total Mean 
4648 100.00 92.96 172.75 
2539 54.63 50.78 78.87 
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J .u.L~ Vect-<Jr Red 
VECTOR RED 6/21/01.005 
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VECTOR RED 6/21/01.002 
VECTOR RED 6/21/01.002 
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File: HUSMC'S ~ 
Patient 10: TAG: 
Gate: G1 
Total Events: 5( 
Marker Left, R 
All 1, I 
M1 1, 
M2 158, f 
File: HUSMC'S . 
Patient 10: TAG: 
Gate: G1 
Total Events: 5( 
Marker Left, R 
All 1, I 
M1 1, 
M2 158, f 
File: HUSMC'S 
Patient 10: TAG 
Gate: G1 
Total Events: 5 


























































','.:: ... "';' .. ' . 
...... 
' .. 
" ,t, I", • 
,': .: 
• ',.I •••• ;: 
.. ~ .. : .. ~ .. 

































o...,.iIoo"t ..... """...,._ .......... ""'I~~ 
1 
Fl2-H 
\~ u A 0 S0''( .. 






















































1'. , " 
',' . ~', .. 
200 
:'" " 



































































































I • ,', 
. . :,,: .. ,;. 
• • I' : I ~ •••• 
1' • • ::. :. ..'~.:. 




: . ' .. :: 
..... : .... -..,. 
,. ... . R1 
.. :' 
. . '" . ': ..... . 
. . ". . . . " " ... , '" 
,' .•• ', • '! • 
.. ".:":' ... 
... :'" ~~ .. :.~ .:~. ~ .... :' . 
.. ',.' ~ .~". . 
• • :.' '-.,1 •. . . 




. .. ' ... 
... 
800 1000 
. . .. ::" 
.... ; ... ;J>:~;~:~:;:. 


































0 200 400 600 800 1000 
FSC-H 
































File: HUSMC'S 7/24/01.009 
Patient 10: T AG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Oate: 24-Jul-1 
Gated Events: 3423 
Total Events: 5000 
Marker Left, Right 
All 1. 9910 
M1 1, 158 
M2 158, 8429 
Events % Gated % Total Mean 
3423 100_00 68.46 1076.34 
1110 32..43 22..20 55.12 






RJe: HUSMCS 7/24/01.009 
Patient 10: TAG=TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Oate: 24-Jul-1 
Gated Events: 3423 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 3423 100.00 68.46 1044.53 610 
M1 1, 158 1103 32.22 22.06 56.41 42 
M2 158, 8429 2314 67.60 46.28 1478.12 610 
Histogram Statistics 
Rle: HUSMC'S 7/24101.009 
Patient 10: T AG= TUBE 
Gate: G1 
Sal"ll'le 10: HUMAN AORTIC SMC'S 
Acquisition Oate: 24-Jul-1 
Gated Events: 3423 
T otaJ Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 3423 100.00 68.46 749.14 594 
M1 1, 158 1242 36.28 24.84 45.22 46 
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Histogram Statistics 
Rle: HUSMC'S 7/24/01.008 
Patient ID: T AG= TUBE 
Gate: G1 
Sample ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left., Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 3393 
Events "10 Gated % Total 
3393 100.00 67.86 










Rle: HUSMC'S 7/24/01.008 
Patient ID: TAG: TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3393 
Total Events: 5000 
Marker Left, Right Events "10 Gated % Total Mean PeakCh 
All 1, 9910 3393 100.00 67.86 1020.62 1155 
M1 1, 158 1174 34.60 23.48 74.79 58 
M2 158, 8429 2211 65.16 44.2.2 1488.17 1155 
Histogram Statistics 
Rle: HUSMC'S 7/24/01.008 
Patient ID: T AG= TUBE 
Gate: G1 
Total Events: 5000" 
Marker Left, Right Events 
All 1, 9910 3393 
M1 1, 158 1303 
M2 158, 8429 2091 
SarTllle 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Ju1-1 
Gated Events: 3393 
% Gated % Total Mean Peak Ch 
100.00 67.86 796.27 704 
38.40 26.06 67.71 54 
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Histogram Statistics 
File: HUSMC'S 7/24/01.011 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
Ml 1, 158 





Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-l 














File: HUSMC'S 7/24/01.011 
Patient 10: T AG= TUBE 
Gate: Gl 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3356 
Ml 1, 158 1116 
M2 158, 8429 2233 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-l 
Gated Events: 3356 
% Gated "10 Total Mean PeakCh 
100.00 67.12 1014.18 813 
33.25 22.32 59.18 38 
66.54 44.66 1460.51 813 
Histogram Statistics 
File: HUSMC'S 7/24/01.011 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3356 
Ml 1, 158 1269 
M2 158, 8429 2090 
SaJ1'l)le 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-l 
Gated Events: 3356 
"10 Gated "10 Total Mean PeakCh 
100.00 67.12 707.39 483 
37.81 25.38 44.55 18 
62.28 41.80 1109.06 483 
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Histogram Statistics 
File: VECTOR RED 6/21/01.001 
Patient 10: A 1 
Gate: G1 
Total Events: 10000 
Sample 10: VECTOR RED 
Acquisition Date: 21-Jun'1 
Gated Events: 6389 
X Parameter: FL 1·H (Log) 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 6389 100.00 63.89 46.80 39 
M1 3, 470 6387 99.97 63.87 46.81 39 
Histogram Statistics 
File: VECTOR RED 6/21/01.001 
Patient 10: A1 
Gate: G1 
Total Events: 10000 
Sample 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 6389 
X Parameter: FL2-H (Log) 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 6389 100.00 63.89 84.33 53 
M1 3, 470 6387 99.97 63.87 84.20 53 
Histogram Statistics 
File: VECTOR RED 6/21/01.001 
Patient 10: A1 
Gate: G1 
Total Events: 10000 
Sample 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 6389 
X Parameter: FL3-H (Log) 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 6389 100.00 63.89 164.55 119 
M1 3, 470 
M2 28, 2288 
6234 
6374 
97.57 62.34 153.49 
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Histogram Statistics 
File: VECTOR RED 6/21/01.003 
Patient ID: A3 
Gate: G1 
Sample ID: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 517 
Total Events: 5190 X Parameter: FL 1-H (Log) 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 517 100.00 9.96 14.28 8 
M1 3, 470 513 99.23 9.88 14.37 8 
Histogram Statistics 
File: VECTOR RED 6/21/01.003 
Patient ID: A3 
Gate: G1 
Sample ID: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 517 
Total Events: 5190 X Parameter: FL2-H (Log) 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 517 100.00 9.96 11.07 18 
M1 3, 470 494 95.55 9.52 11.49 18 
Histogram Statistics 
File: VECTOR RED 6/21/01.003 
Patient ID: A3 
Gate: G1 
Total Events: 5190 
Marker Left, Right Events % Gated 
All 1, 9910 517 100.00 
M1 3, 470 499 96.52 
M2 28, 2288 84 16.25 
Sample ID: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 517 
X Parameter: FL3-H (Log) 
% Total Mean PeakCh 
9.96 17.83 18 
9.61 18.41 18 
1.62 45.62 29 
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Histogram Statistics 
Rle: HUSMCS 7/24/01.004 
Patient ID: TAG=TUBE 
Gate: G1 
T otai Events: 5000 
Marker Left, Right Events 
All 1, 9910 3002 
M1 1, 289 970 
M2 289, 9910 2034 
Sal1llle ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3002 
% Gated % Total Mean PeakCh 
100.00 60.04 1124.17 858 
32.31 19.40 79.62 50 
67.75 40.68 1621.49 858 
Histogram Statistics 
Rle: HUSMC'S 7/24/01.005 
PatiemID:TAG=TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3479 
M1 1, 289 832 
M2 289, 9910 2649 
Salll'le lD: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3479 
% Gated % Total Mean PeakCh 
100.00 69.58 1398.67 1027 
23.91 16.64 87.29 269 
76.14 52.98 1809.71 1027 
,J ~ .•.. ( ~i\., 
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Histogram Statistics 
File: HUSMC'S 7/24/01.006 
Patient ID: TAG=TUBE 
Gate: G1 
Total Evems: 5000 
Marker Left, Right Events 
All 1, 9910 2591 
M1 1, 289 1159 
M2 289, 9910 1433 
'-:.. .. ~ 
C.- a 1'01. /...~:' I 
Sample ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2591 
% Gated % Total Mean Peak Ch 
100.00 51.82 778.40 578 
44.73 23.18 87.16 51 
55.31 28.66 1337.13 578 
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Histogram Statistics 
File: HUSMC'S 7/24101.001 Sal'l1lle ID: HUMAN AORTIC SMC'S 
Patient ID: TAG= lUBE Acquisition Date: 24-Jul-1 
Gate: G1 Gated Events: 2133 
Total Events: 4425 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 2133 100.00 48.20 778.00 34 
M1 1, 289 1055 49.46 23.84 81.92 34 
M2 289, 9910 1082 50.73 24.45 1454.91 874 
Histogram Statistics 
File: HUSMC'S 7/24101.002 
Patient ID: TAG=lUBE 
Sal'l1lle ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
( i Lt..-I Gate: G1 
Iv,Lle- -
Total Events: 4785 
Gated Events: 2757 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 2757 100.00 57.62 976.76 813 
M1 1, 289 1082 39.25 22.61 81.27 53 
M2 289, 9910 1675 60.75 35.01 1555.22 813 
Histogram Statistics 
File: HUSMC'S 7/24101.003 
Patient ID: T AG= TUBE 
Gate: G1 
Sample ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Total Events: 5235 
Marker Left, Right 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
Gated Events: 2905 
Events % Gated % Total Mean 
2905 100.00 55.49 1046.99 
1094 37.66 20.90 88.79 
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o 200 400 600 8001000 
FSC-H 
Histogram Statistics 
Rle: HUSMC'S 7/24/01.001 Safl'llie ID: HUMAN AORTIC SMC'S 
Patient ID: T AG= TUBE Acquisition Date: 24-Jul-1 
Gate: No Gate Gated Events: 4425 
Total Events: 4425 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 4425 100.00 100.00 402.17 34 
M1 1, 289 3296 74.49 74.49 52.57 34 
M2 289, 9910 1134 25.63 25.63 1417.81 573 
Histogram Statistics 
File: HUSMC'S 7/24/01.002 
Patient ID: TAG= TUBE 
Gate: No Gate 
Sal1"ple ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 4785 
Total Events: 4785 
Marker Left, Right 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
Events % Gated % Total Mean Peak Ch 
4785 100.00 100.00 584.11 53 
3060 
1725 
63.95 63.95 53.41 




File: HUSMC'S 7/24/01.003 
Patient ID: TAG=TUBE 
Gate: No Gate 
Sample ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 5235 
Total Events: 5235 
Marker Left, Right 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
Events % Gated % Total 
5235 100.00 100.00 
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o 200 400 600 8001000 
FSC-H 
Histogram Statistics 
Rle: HUSMC'S 7/24/01.010 
Patient 10: TAG:: TUBE 
Gate: No Gate 
Total Events: 5000 
Sall1>le 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 
M1 1, 289 
M2 289,9910 
5000 100.00 100.00 687.22 
2927 58.54 58.54 56.78 





Rle: HUSMC'S 7/24/01.011 
Patient 10: TAG::TUBE 
Gate: No Gate 
Sarrple 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-l 
Gated Events: 5000 
Total Even,ts: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 5000 100.00 100.00 696.53 813 
Ml 1, 289 2925 58.50 58.50 59.41 38 
M2 289, 9910 2078 41.56 41.56 1592.74 813 
Histogram Statistics 
File: HUSMC'S 7/24/01.012 
Patient 10: TAG:: TUBE 
Gate: No Gate 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 5000 
Ml 1, 289 3253 
M2 289, 9910 1750 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-l 
Gated Events: 5000 
% Gated % Total Mean Peak Ch 
100.00 100.00 593.30 40 
65.06 65.06 53.45 40 
35.00 35.00 1596.29 743 
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o 200 400 600 8001000 
FSC-H 
Statistics 
Sarrple 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3079 
% Gated % Total Mean Peak Ch 
100.00 61.58 1084.18 851 
34.10 21.00 87.17 45 
65.96 40.62 1598.84 851 
i.c:tnnr::.m Statistics 
Sarrple 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3019 
% Gated % Total Mean Peak Ch 
100.00 60.38 1116.03 813 
32.99 19.92 89.03 49 
67.11 40.52 1619.69 813 
lS.nnr"rn Statistics 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2752 
% Gated % Total Mean Peak Ch 
100.00 55.04 1035.76 743 
38.37 21.12 80.99 
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0 200 400 600 8001000 
FSC-H 
Histogram Statistics 
'd/';":; I), L \j{L Rle: HUSMC'S 7/2~01.007 
Patient 10: TAG= TUBE 
Gate: Gl 
Total Events: 5000 
Marker Left, 
All 1, 9910 
Ml 1, 289 
M2 289, 9910 
Events % Gated % Total Mean 






Rle: HUSMC'S 7/2~01.008 
SO ,U. L vR Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker 
All 1, 9910 
Ml 1, 289 
M2 289, 9910 
Events % Gated % Total Mean 
3042 100.00 60.84 1125.72 
1105 36.32 22.10 1 08.28 
1940 63.77 38.80 1703.94 
Histogram Statistics 
Rle: HUSMC'S 7/24/01.009 
Patient 10: T AG= TUBE 
Gate: G1 
Acquisition Date: 24-Jul-l 
Gated Events: 3120 
Total Events: 5000 
Marker Left, Ri Events % Gated % Total Mean 
All 1, 9910 3120 100.00 62.40 1137.90 
M1 1, 289 1011 32.40 20.22 88.81 
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File: HUSMC'S 7/24101.004 
Patient ID: TAG=TUBE 
Gate: No Gate 
Total Events: 5000 
Sarrple ID: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gated Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 5000 100.00 100.00 695.06 858 
M1 1, 289 
M2 289, 9910 
2913 
2089 
58.26 58.26 52.52 




Rle: HUSMC'S 7/24101.005 
Patient ID: TAG=TUBE 
Gate: No Gate 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 5000 
M1 1, 289 2301 
M2 289, 9910 2701 
. ..;._.~.t·;·: 
Sarrple ID: HUMAN AORTIC SMCS 
-··Acquisition Date: 24-Jul-1 
Gated Events: 5000 
% Gated % Total Mean PeakCh 
100.00 100.00 989.87 1027 
46.02 46.02 56.01 29 
54.02 54.02 1784.91 1027 
Histogram Statistics 
C ~(':~rc i 
File: HUSMC'S 7/24101.006 
Patient ID: T AG= TUBE 
Gate: No Gate 
Sample ID: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left. Right 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
Gated Events: 5000 
Events % Gated % Total 
5000 100.00 100.00 
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Histogram Statistics 
File: HUSMC'S 7/24/01.001 
Patient ID: TAG=TUBE 
Gate: G1 
Sample ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Total Events: 4425 
Marker Left, Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 2494 
Events % Gated % Total Mean 
2494 100.00 56.36 709.29 
1212 48.60 27.39 55.80 






File: HUSMC'S 7/24/01.001 
Patient ID: TAG=TUBE 
Gate: G1 
Sample ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Total Events: 4425 
Marker Left, Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 2494 
Events % Gated % Total Mean 
2494 100.00 56.36 680.25 
1228 
1262 
49.24 27.75 55.72 






File: HUSMC'S 7/24/01.001 
Patient ID: T AG= TUBE 
Gate: G1 
Sample ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2494 
Total Events: 4425 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 2494 100.00 56.36 495.12 52 
M1 1, 158 1356 54.37 30.64 41.29 52 
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Histogram Statistics 
File: HUSMC'S 7/24/01.004 Sample ID: HUMAN AORTIC SMC'S 
Patient ID: T AG= TUBE Acquisition Date: 24-Jul-1 
Gate: G1 Gated Events: 3294 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 3294 100.00 65.88 1079.18 9140 
M1 1, 158 1087 33.00 21.74 54.24 43 
M2 158, 8429 2160 65.57 43.20 1418.84 843 
Histogram Statistics 
File: HUSMC'S 7/24/01.004 Sample ID: HUMAN AORTIC SMC'S 
Patient ID: T AG= TUBE Acquisition Date: 24-Jul-1 
Gate: G1 Gated Events: 3294 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 3294 100.00 65.88 1031.80 858 
M1 1, 158 1094 33.21 21.88 53.94 50 
M2 158, 8429 2192 66.55 43.84 1477.19 858 
Histogram Statistics 
File: HUSMC'S 7/24/01.004 
Patient ID: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3294 
M1 1, 158 1206 
M2 158, 8429 2090 
Sarlllie ID: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3294 
% Gated % Total Mean PeakCh 
100.00 65.88 732.91 632 
36.61 24.12 39.99 55 
63.45 41.80 1132.19 632 
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Histogram Statistics 
File: HUSMC'S 7/24/01.005 
Patient 10: TAG=TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 3739 
Events % Gated % Total Mean 
3739 100.00 74.78 1365.73 
908 24.28 18.16 55.97 






File: HUSMC'S 7/24/01.005 
Patient 10: T AG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 3739 
Events % Gated % Total Mean 
3739 100.00 74.78 1307.94 
911 24.36 18.22 56.64 






File: HUSMC'S 7/24/01.005 
Patient 10: TAG=TUBE 
Gate: G1 
SarIlJle 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3739 
Total Events: 5000 
Marker Left, Right Events 0/0 Gated % Total Mean Peak Ch 
All 1, 9910 3739 100.00 74.78 935.87 661 
M1 1, 158 1027 27.47 20.54 43.42 43 
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Histogram Statistics 
File: HUSMC'S 7/2~01.006 
Patient ID: T AG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMas 
Acquisition Date: 24-Jul-1 
Gated Events: 2975 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Events % Gated % Total Mean 
2975 100.00 59.50 701.59 
1305 43.87 26.10 56.71 






Rle: HUSMC'S 7/24/01.006 
Patient 10: TAG=TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gated Events: 2975 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 2975 100.00 59.50 689.03 578 
M1 1, 158 
M2 158, 8429 
1313 
1664 
44.13 26.26 57.19 




File: HUSMC'S 7/24/01.006 
Patient ID: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 2975 
M1 1, 158 1474 
M2 158, 8429 1503 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2975 
% Gated % Total Mean Peak Ch 
100.00 59.50 487.56 496 
49.55 29.48 43.73 47 













530 nM (FITC) 
585 nM: PI/PE 
>650 nM: RED 
525 NM 575 NM 
